129 related articles for article (PubMed ID: 27931859)
1. Contemporary Trends in the Management and Outcomes of Patients With Familial Hypercholesterolemia in Canada: A Prospective Observational Study.
Brunham LR; Cermakova L; Lee T; Priecelova I; Alloul K; de Chantal M; Francis GA; Frohlich J
Can J Cardiol; 2017 Mar; 33(3):385-392. PubMed ID: 27931859
[TBL] [Abstract][Full Text] [Related]
2. Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study.
D'Erasmo L; Commodari D; Di Costanzo A; Minicocci I; Polito L; Ceci F; Montali A; Maranghi M; Arca M
Nutr Metab Cardiovasc Dis; 2020 Oct; 30(11):2027-2035. PubMed ID: 32830020
[TBL] [Abstract][Full Text] [Related]
3. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
Vishwanath R; Hemphill LC
J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
[TBL] [Abstract][Full Text] [Related]
4. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
[TBL] [Abstract][Full Text] [Related]
5. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
Béliard S; Boccara F; Cariou B; Carrié A; Collet X; Farnier M; Ferrières J; Krempf M; Peretti N; Rabès JP; Varret M; Vimont A; Charrière S; Bruckert E;
Atherosclerosis; 2018 Oct; 277():334-340. PubMed ID: 30270068
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
[TBL] [Abstract][Full Text] [Related]
7. Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort.
Peretti N; Vimont A; Mas E; Lemale J; Reynaud R; Tounian P; Poinsot P; Restier L; Paillard F; Pradignac A; Pucheu Y; Rabès JP; Bruckert E; Gallo A; Béliard S
Arch Pediatr; 2024 Apr; 31(3):188-194. PubMed ID: 38538465
[TBL] [Abstract][Full Text] [Related]
8. Nine-year overview of dyslipidemia management in children with heterozygous familial hypercholesterolemia: a university hospital outpatient lipid clinic project in Northwestern Greece.
Benekos T; Kosmeri C; Vlahos A; Milionis H
J Pediatr Endocrinol Metab; 2020 Apr; 33(4):533-538. PubMed ID: 32084003
[TBL] [Abstract][Full Text] [Related]
9. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.
Besseling J; Kindt I; Hof M; Kastelein JJ; Hutten BA; Hovingh GK
Atherosclerosis; 2014 Mar; 233(1):219-23. PubMed ID: 24529147
[TBL] [Abstract][Full Text] [Related]
10. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
[TBL] [Abstract][Full Text] [Related]
11. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
Arca M
Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.
Pijlman AH; Huijgen R; Verhagen SN; Imholz BP; Liem AH; Kastelein JJ; Abbink EJ; Stalenhoef AF; Visseren FL
Atherosclerosis; 2010 Mar; 209(1):189-94. PubMed ID: 19818960
[TBL] [Abstract][Full Text] [Related]
13. The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients.
Béliard S; Millier A; Carreau V; Carrié A; Moulin P; Fredenrich A; Farnier M; Luc G; Rosenbaum D; Toumi M; Bruckert E;
J Clin Lipidol; 2016; 10(5):1129-1136.e3. PubMed ID: 27678429
[TBL] [Abstract][Full Text] [Related]
14. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
Kawashiri MA; Nohara A; Higashikata T; Tada H; Nakanishi C; Okada H; Konno T; Sakata K; Hayashi K; Inazu A; Mabuchi H; Yamagishi M
Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
[TBL] [Abstract][Full Text] [Related]
16. Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry.
Saltijeral A; Pérez de Isla L; Alonso R; Muñiz O; Díaz-Díaz JL; Fuentes F; Mata N; de Andrés R; Díaz-Soto G; Pastor J; Pinilla JM; Zambón D; Pinto X; Badimón L; Mata P;
Rev Esp Cardiol (Engl Ed); 2017 Jun; 70(6):444-450. PubMed ID: 27913073
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
18. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label).
Braamskamp MJAM; Langslet G; McCrindle BW; Cassiman D; Francis GA; Gagne C; Gaudet D; Morrison KM; Wiegman A; Turner T; Miller E; Kusters DM; Raichlen JS; Martin PD; Stein EA; Kastelein JJP; Hutten BA
Circulation; 2017 Jul; 136(4):359-366. PubMed ID: 28592434
[TBL] [Abstract][Full Text] [Related]
19. A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia.
Langslet G; Breazna A; Drogari E
J Clin Lipidol; 2016; 10(5):1153-1162.e3. PubMed ID: 27678432
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.
Shah P; Glueck CJ; Jetty V; Goldenberg N; Rothschild M; Riaz R; Duhon G; Wang P
Lipids Health Dis; 2016 Aug; 15(1):132. PubMed ID: 27538393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
